European neuroborreliosis: neuropsychological findings 30 months post-treatment by Eikeland, Randi et al.
European neuroborreliosis: neuropsychological ﬁndings 30 months
post-treatment
R. Eikelanda, U. Ljøstadb, A˚. Myglandb,c,d, K. Herlofsona and G. C. Løhaugene,f
aDepartment of Neurology, Sørlandet Hospital, Arendal; bDepartment of Neurology, Sørlandet Hospital, Kristiansand; cInstitute of Clinical
Medicine, University of Bergen, Bergen; dDepartment of Rehabilitation, Sørlandet Hospital, Kristiansand; eDepartment of Paediatrics and
Rehabilitation, Sørlandet Hospital, Arendal; and fDepartment of Laboratory Medicine, Childrens and Womens Health, NTNU, Trondheim,
Norway
Keywords:
cognition, executive func-
tions, Lyme disease, Lyme
neuroborreliosis, memory
Received 5 May 2011
Accepted 31 August 2011
Background: The aim of this study was to compare neuropsychological (NP) func-
tioning in patients with Lyme neuroborreliosis (LNB) 30 months after treatment to
matched controls.
Methods: We tested 50 patients with LNB and 50 controls with the trail-making test
(TMT), Stroop test, digit symbol test, and California Verbal Learning test (CVLT). A
global NP sumscore was calculated to express the number of low scores on 23 NP
subtasks.
Results: Mean scores were lower amongst LNB-treated patients than amongst con-
trols on tasks assessing attention/executive functions: (Stroop test 4: 77.6 vs. 67.0,
P = 0.015), response/processing speed (TMT 5: 23.4 vs. 19.2, P = 0.004), visual
memory (digit symbol recall: 6.6 vs. 7.2, P = 0.038), and verbal memory (CVLT list
B: 4.68 vs. 5.50, P = 0.003). The proportion of patients and controls with NP sum-
scores within one SD from the mean in the control group (deﬁned as normal) and
between one and two SD (deﬁned as deﬁcit) were similar, but more LNB-treated
patients than controls had a sumscore more than two SD from the mean (deﬁned as
impairment) (8 vs. 1, P = 0.014).
Conclusions: As a group, LNB-treated patients scored lower on four NP subtasks
assessing processing speed, visual and verbal memory, and executive/attention func-
tions, as compared to matched controls. The distribution of NP dysfunctions indicates
that most LNB-treated patients perform comparable to controls, whilst a small sub-
group have a debilitating long-term course with cognitive problems.
Introduction
European Lyme neuroborreliosis (LNB) typically
presents as a subacute, painful, and lymphocytic
meningoradiculitis (Bannwarths syndrome) whereas
central nervous system involvement with encephalitis
or myelitis is rare [1]. The objective manifestations of
LNB usually disappear or stabilize after antibiotic
treatment, but 10–50% of the patients report persist-
ing complaints such as fatigue, cognitive problems,
myalgia, arthralgia, or reduced health-related quality
of life (HRQoL) [2–4]. If these complaints persist more
than 6 months after antibiotic therapy, the condition
is often called post-Lyme disease syndrome [5]. The
prevalence of objective cognitive deﬁcits post-LNB is
debated [4]. Studies addressing this issue vary sub-
stantially regarding methods and patient selection [6–
11], and most studies are conducted in the United
States (US). In brief, these studies have found diﬀerent
patterns of reduced processing speed, memory, and
executive/attention problems amongst patients with
post-Lyme syndrome. As both the Borrelia genotype
and the clinical picture of Lyme disease in the US
diﬀer somewhat from what we ﬁnd in Europe, the
study results are not necessarily transferable to Euro-
pean patients [1].To our knowledge, there is only one
controlled European post-LNB study that includes
standardized neuropsychological (NP) assessment of
cognitive functions [12]. In this study, they found
deﬁcits related to memory, mental ﬂexibility, verbal
association, and articulation amongst patients with
LNB. This study was conducted before standard
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therapy for LNB was established, and not all of the 20
included patients had received antibiotics.
The aim of our study was to compare NP functioning
in a group of well-characterized European adult
patients with LNB 30 months after treatment to a
matched control group.
Methods
Study design
Case–control follow-up.
Patients and controls
From 2004 to 2008, 102 consecutive adult patients from
nine hospitals in Norway were included in a LNB treat-
ment study, comparing doxycycline and ceftriaxone [13].
Of practical and geographical reasons, we only included
patients from the two hospitals in Agder County, the
highest endemic region regarding Borrelia infections in
Norway. Clinical score at pre-treatment and 4 months
post-treatment as well as the type of treatment did not
diﬀer signiﬁcantly between the patients included in this
study and the rest of the patients in the treatment trial
(data not shown). Fifty-seven patients were invited by
letter to participate 30 months (range 27–34) after
treatment, and 50 persons consented and were included.
Detailed study design, inclusion, and diagnostic criteria
are described elsewhere [3].
Each patient with LNB brought a control person
from the same geographical area, matched for age,
gender, and education level. Exclusion criterion for the
controls was a typical history of LNB. Serological
testing of the controls was not carried out as 15–20% of
the inhabitants of Agder County are known to have
anti-Borrelia antibodies without any history of LNB.
Patient characteristics are shown in Table 1.
Clinical variables
The examinations took place at Sørlandet Hospital by
one experienced neurologist (RE). All participants were
informed that the NP tests assessed diﬀerent aspects of
cognition, like memory and attention, and they were
encouraged to perform their best in every test.
A trained neuropsychologist blinded to group
adherence scored the NP tests. Clinical and demo-
graphic data were collected through a semi-structured
interview and clinical neurological examination. Before
treatment, 80% of the patients had a complete or par-
tial Bannwarts syndrome, and 8% had symptoms
suggesting involvement of the central nervous system
(myelitis, ataxia, or confusion). Fifty percent were
treated with oral doxycycline and 50% with IV ceftri-
axone. Sixty-eight percent were classiﬁed as deﬁnite
LNB and 32% as possible LNB [14]. The scores of the
HRQoL questionnaire Short-Form 36 (SF-36), fatigue
severity scale (FSS), and Montgomery and A˚sberg
Depression Rating Scale (MADRS) are previously
published; Physical Component Summary (PCS) of SF-
36 was 44, Mental Component Summary (MCS) 49,
FSS 3.5, and MADRS 3.1 [3]. Three patients had anti-
TBE IgG antibodies in serum, and none had anti-TBE
IgM antibodies. We did not test for Anaplasma, but
none of the patients had a clinical picture or blood
count suggestive of Anaplasma infection. The selection
of NP tests was based on a review of relevant studies
[4,8,10,11,15]. The NP tests were administered in a ﬁxed
order, but short breaks were permitted if needed.
Cognitive assessments, neuropsychological (NP) tests
Executive functions and attention
Trail-making test (TMT 1–4) assesses attention and
ﬂexibility in solving problems on visual–motor tasks
[16]:
TMT 1 (visual scanning): Tick a speciﬁc number
amongst an array of letters and numbers.
Table 1 Characteristics of LNB-treated patients and controls (previ-
ously published) [3]
Variable
LNB-treated
patients
(n = 50)
Controls
(n = 50) P-value
Age years, mean (range) 55 (21–76) 56 (20–78) ns
Gender male n (%) 29 (58) 29 (58) ns
Married/partner yes n (%) 44 (88) 44 (88) ns
Secondary education
0–3 years/4–7 years/‡7
years n
25/15/10 23/13/14 ns
Coexisting diseases n (%)
Somatic 25 (50) 29 (58) ns
Previous/present psychiatric 10 (20) 8 (20) ns
Out of work n (%)
Total 18 (36) 16 (32) ns
Because of LNB 5 (10) 0 (0) ns
Other illness 5 (10) 4 (8) ns
Old-age 6 (12) 11 (22) ns
Student/unemployed 1 (2)/1 (2) 0 (0)/1 (2) ns
Reported subjective
complaints n (%)
Malaise 11 (22) 0 (0) <0.001
Fatigue 25 (50) 8 (16) 0.001
Pain 16 (32) 21 (42) ns
Memory problems 23 (46) 5 (10) <0.001
Concentration problems 17 (34) 4 (8) 0.003
Paraesthesias 17 (34) 7 (14) 0.034
ns, not signiﬁcant; SD, standard deviation; LNB, Lyme neuroborrel-
iosis.
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TMT 2: Connect numbers in rising order.
TMT 3: Connect letters in alphabetical order.
TMT 4: (primary executive/attention function): Con-
nect numbers and letters in correct order (i.e., switching
between two sets of rules).
Raw scores are the time (s) used to complete the tasks.
The color-word interference tasks 1–4 are an adapted
version of the Stroop test [16] that assesses the ability to
inhibit a prepotent reaction (impulse control);
Stroop 1: Name colors.
Stroop 2: Read color names.
Stroop 3: Avoid reading the word and instead name the
ink color in which the word is written.
Stroop 4: Name the ink color on all words, except those
placed within a square, which should be read.
The last two conditions are the primary executive tests
and require both the inhibition of reading and the
ability to switch between rules.
Raw scores are the time (s) used to complete the
tasks.
Processing speed/response speed
The digit symbol test [part of the Wechsler Adult
Intelligence scale (WAIS-III)]: Copy symbols paired
with numbers during a 120-s interval.
Raw scores are the number of correctly copied sym-
bols [16].
TMT 5: Draw a line between dots as fast as possible.
Raw score is the time (s) used to complete the task.
Memory assessment
Digit symbol cued and free recall test assess visual
learning.
Digit symbol cued recall test: Combine symbols and
numbers recalled from the digit symbol test.
Digit symbol-free recall test: Write down all symbols
recalled from the digit symbol test.
The California Verbal Learning Test (CVLT)
assesses verbal learning, short- and long-term memory,
and recognition:
CVLT 1–5 (assesses learning by repetition):
Remember a word list during ﬁve oral presentations.
CVLT list B: Remember a second word list presented
once.
CVLT free and cued short recall: Recall the
original list after the distracter list in free and cued
manner.
CVLT free and cued long recall: After a 20-min
brake, recall the original list [17].
The optional trail of the CVLT-II, long delay forced-
choice recognition, was included to examine the degree
of individual eﬀort: Pick the word from the original list
amongst two diﬀerent words presented immediately
after the long delay test [17].
Ethics
All participants gave written informed consent. The
study was approved by the Regional Committee for
Medical Research Ethics in Southern Norway, and by
the Norwegian Data Inspectorate. This trial is a follow-
up study on the treatment trial registered with Clini-
calTrials.gov number NCT00138801.
Statistical analysis
The statistical software SPSS version 16 (Statistical
Package for Social Sciences Inc., Chicago, IL, USA)
was used for all analyses. The groups were compared by
paired t-test and Wilcoxon signed-rank test for paired
continuous data, and McNemar test for paired cate-
gorical data. Paired test was chosen because of the
matched one-to-one cases study design. P-values <0.05
were regarded as signiﬁcant. The results are reported as
mean raw scores with standard deviations (SD) or
proportions. To achieve a dimensionless quantity, the
scores for each NP subtest were transformed into Z-
scores. The Z-score represents the distance between the
patients raw score and the mean in the control group.
(Zi = (Xi ) Zcon)/SDcon where Zi is the individual
Z-score of the ith patient, Xi is the individuals test raw
score, Zcon is the mean test result of the control group,
and SDcon is the mean SD of the control group.) To
correlate the NP test results with other ﬁndings, we used
Pearsons correlation coeﬃcient for continuous data
and Mann–Whitney test for categorical data.
The four NP tests consisted of 23 subtasks, and a
sumscore was calculated expressing the number of NP
subtasks with scores £1 SD from the mean in the
control group (range 0–23). The sumscores were then
categorized into three groups: normal, 1–5 (£1 SD from
the mean sumscore in the control group); deﬁcit, 6–8
(>1 – £2 SD from the mean sumscore in the control
group); and impairment, 9–23 (>2 SD from the mean
sumscore in the control group).
Missing data were dealt with by imputing the mean
score from the respective patient or control group. If
the scores were missing because of inability to perform
the test at hand, by imputing the lowest obtained score
in the respective group. Four patients missed in average
2.5 of the 23 subtasks, and four controls missed on
average 1.5 of the 23 subtasks.
Results
Mean NP test results are presented in Table 2.
None failed on the CVLT long delay forced-choice
recognition, indicating adequate test eﬀort in all
participants.
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Mean scores on tests assessing attention/executive
functions (Stroop 4), processing speed/response speed
(TMT 5), visual memory (digit symbol recall), and
verbal memory (CLVT list B) were lower amongst
LNB-treated patients than amongst matched controls.
More patients than controls scored £1 SD of the mean
in the control group on processing speed (TMT 5) and
visual memory (digit symbol recall), 14 vs. 7
(P = 0.046) and 10 vs. 3 (P = 0.038), respectively.
Figure 1 shows mean Z-score in each NP test.
Figure 2 shows the distribution of sumscores in
patients and controls.
Table 2 Neuropsychological test results in patients treated for Lyme Neuroborreliosis (n = 50) and controls (n = 50). Numbers are raw scores
(standard deviation)
Function Measure Patients Controls P-value
Executive TMT 1 (s) 24.8 (8.6) 23.1 (7.1) 0.476
Functions TMT 2 (s) 39.0 (18.2) 34.8 (14.1) 0.202
TMT 3 (s) 46.9 (38.6) 39.2 (21.5) 0.146
TMT 4 (s) 101.4 (55.1) 101.9 (46.3) 0.332
Stroop 1 (s) 31.6 (7.4) 30.6 (6.8) 0.558
Stroop 2 (s) 23.0 (4.9) 22.0 (3.7) 0.312
Stroop 3 (s) 64.8 (24.1) 59.2 (17.6) 0.102
Stroop 4 (s) 77.6 (30.1) 67.0 (16.3) 0.015*
Processing speed Digit symbol (number of symbols) 41.8 (12.8) 45.5 (11.5) 0.060
TMT 5 (s) 28.4 (9.7) 19.2 (6.7) 0.004*
Visual memory Digit symbol, free recall (number of symbols) 6.6 (1.6) 7.2 (1.3) 0.038*
Digit symbol, cued recall (number of symbols) 9.7 (4.7) 10.6 (4.6) 0.261
Verbal memory CVLT trail 1 (number of words) 5.72 (1.9) 5.58 (2.0) 0.845
CVLT trail 2 (number of words) 8.18 (2.4) 8.86 (2.7) 0.206
CVLT trail 3 (number of words) 9.44 (2.4) 9.96 (2.8) 0.443
CVLT trail 4 (number of words) 10.24 (2.1) 11.12 (2.6) 0.094
CVLT trail 5 (number of words) 11.02 (2.4) 11.46 (2.6) 0.412
CVLT trail 1-5 (number of words) 44.60 (9.1) 46.98 (11.5) 0.295
CVLT list B (number of words) 4.68 (1.9) 5.50 (2.0) 0.014*
CVLT Short delay (number of words) 9.36(3.4) 10.18 (3.1) 0.255
CVLT Short delay cued (number of words) 11.58 (2.5) 11.33 (4,00) 0.780
CVLT Long delay (number of words) 10.34 (3.4) 11.14 (3.1) 0.426
CVLT Long delay cued (number of words) 11.50(3.4) 11.66 (3.4) 0.780
TMT, Trail Making Test. CVLT, California Verbal Learning Test. *Signiﬁcance level P < 0.05.
Figure 1 Patients neuropychological test results displayed as z-scores, i.e. standard deviation above or below the mean in the control
group. Y = 0 is mean in control group. TMT, trail-making test; CVLT, California Verbal Learning Test.
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Correlations between NP test results, self-perceived
symptoms, and occupational functioning are shown in
Table 3.
We found no correlation between NP test results and
fatigue (self-reported fatigue and FSS score), depres-
sion, subjective reported malaise, or HRQoL in the
LNB-treated patients.
Discussion
We found that mean scores on four NP subtests
assessing attention/executive functions (Stroop 4),
processing speed (TMT 5), visual (digit symbol-free
recall) and verbal (CVLT list B) memory were lower
amongst European patients treated for LNB 30 months
earlier than amongst matched controls. These ﬁndings
indicate some dysfunction in these NP domains after
treated LNB. To obtain a better understanding of the
distribution and degree of NP dysfunction amongst our
LNB-treated patients, we looked more detailed into the
individual scores. In NP terms, scores worse than one
SD from the mean in a control group are often con-
sidered as deﬁcits, whilst scores worse than two SD are
considered impairments. Analyses based on this
assumption showed that more LNB-treated patients
than controls obtained a score in accordance with an
NP deﬁcit on TMT 5 and on digit symbol-free recall
test. Furthermore, we calculated an NP sumscore and
categorized into groups based on one and two SD from
the mean in the control group. The proportion of
patients and controls with sumscores within one SD
(deﬁned as normal) and between one and two SD (de-
ﬁned as deﬁcit) were similar, but more LNB-treated
patients than controls had a sumscore more than two
SD from the mean (deﬁned as impairment). The results
from the sumscore analyses illustrate that there is a
wide range of performance on the NP tests in both
patients and controls and that the vast majority of
LNB-treated patients recover to an NP function com-
parable with the normal population. However, a small
subgroup has a debilitating long-term course with some
NP dysfunction.
The pattern of NP deﬁcits amongst our LNB-treated
patients was characterized by reduced impulse control
and processing speed and poorer ability to verbal
learning. Daily life consequences of these deﬁcits may
be reduced the ability to quickly perform a given task or
come up with a solution to a given problem. Reduced
learning and remembering of verbal material after just
one presentation may cause problems recalling mes-
sages and information from lectures or discussions.
Earlier studies have not found a convincing cognitive
deﬁcit proﬁle after LNB [4], and results from various
tests in diﬀerent studies are deviating. Some previous
studies have, in contrast to ours, revealed deﬁcits on the
TMT 1–4 subtasks assessing attention/executive func-
tions, [8,12,18], but deﬁcits on TMT 5 assessing pro-
cessing speed are also reported in accordance with our
ﬁndings [8]. Pollina et al. [19] showed that performance
on tasks like the TMT 5 and digit symbol could not be
Patients n = 50 Controls n = 50
45 (90)
4 (8) 
1 (2) 
P-value
0.067 
1.000 
0.014 
NP sumscore* categories 
Deficit 6–8 (>1–≤2 SD from mean sumscore in the control group) n (%)
Impairment >8 (> 2 SD from mean sumscore in the control group) n (%)
Normal 0–5 (≤1 SD from mean sumscore in the control group) n (%) 38 (76) 
8 (16) 
4 (8)
Figure 2 Differences in neuropsychological (NP) sumscores in LNB treated patients and controls. NP sumscore, number of NP subtasks
with scores £1 SD from the mean in the control group (range 0–23). Mean sumscores (SD), LNB treated patients 3.9 (4.2) and Controls 2.6
(3.1).
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explained by sensory, perceptual, or motor deﬁcits and
could thus be interpreted as a speciﬁc impairment in
processing speed. In a study of patients with symp-
tomatic post-Lyme disease, Keilp et al. [10] found mild
levels of impairment in processing speed and memory,
correlated for intelligence (IQ). Other studies have
reported more severe deﬁcits in verbal memory than we
did. Benke and Shadick reported problems with both
short- and long-time verbal memory in patients with
LNB [8,12], whilst Kalish did not [9]. Twenty patients
with LNB in a European study were similar to our
cohort on several variables, but they reported more
extensive verbal-, but not visual memory problems [12].
A recent study of adolescents showed more visual than
verbal memory problems like we did in adults [6], and
this suggests that the verbal memory is more robust and
less aﬀected by LNB. The diversity in study results
could partly be explained by the diﬀerence in patient
selection criteria [7,8,19–21].
When comparing the NP results to HRQoL, sub-
jective memory and concentration problems, subjective
incomplete recovery, and self-reported reduced occu-
pational function owing to post-LNB, the only corre-
lations were between low scores on tasks assessing
inhibition (Stroop 4) and subjective memory problems
and low scores on processing/response speed (TMT-5)
and subjective incomplete recovery. These ﬁndings are
diﬃcult to explain, but we know from other studies that
subjective reported functioning does not always corre-
late with the objective ﬁndings [15]. Possible explana-
tions may be that patients interpret attention and
impulse control problems as memory problems.
Awareness of deﬁcits is probably also inﬂuenced by the
individual demands at work and daily life and depen-
dent of individual skills and ability to compensate.
Overlapping NP tests could have given a more reliable
cognitive proﬁle in our study, but because of the time
aspect, we chose test that assesses diﬀerent aspects of
cognition.
The underlying pathogenesis of post-Lyme syndrome
and associated cognitive deﬁcits is unknown. Amongst
the theories discussed are sequelae after the initial
bacterial damage, a post-infectious autoimmune reac-
tion, a not completely eradicated infection, co-infection,
or psychiatric comorbidity [22]. Earlier imaging studies
have not revealed ﬁndings in the central nervous system
that explain the cognitive deﬁcits, but Fallon found
more abnormalities in temporal, parietal, and limbic
areas in a study of cerebral blood ﬂow and metabolic
rate in persistent Lyme encephalopathy patients as
compared to controls [23]. Another study found a
correlation with low test scores on memory and visuo-
spatial organization and ﬂow reductions in white matter
index, particulary in the posterior temporal and parietal
lobes bilaterally when doing NP tests simulatously with
measuring Xenon(133)-regional cerebral blood ﬂow
[24]. Studies have shown that additional antibiotics
after treated LNB may only have transient eﬀects on
long-term complaints, and persistent ongoing infection
is thus unlikely an explanation of these problems
[11,15,25,26]. In a previous publication, we have shown
that mean score on MADRS amongst our patients did
not indicate depression as a reason for the dysfunction
[3], and co-infections with other tick-borne diseases do
not seem to play a role.
Limitations of our study are the non-blinded testing
and lack of matching regarding intelligence. We tried to
minimize these problems by having a neuropsychologist
Table 3 Correlation between NP test results and self-perceived function and occupational function in LNB-treated patients
Subjective reported
functioning
TMT5 Stroop 4 Digit symbol-free recall CVLT list B
Seconds
Mean (SD) P-value
Seconds
Mean (SD) P-value
Symbols recalled
Mean (SD) P-value
Words recalled
Mean (SD) P-value
Memory problems
Yes n = 23 24.4 (7.0) 0.064 88.5 (35.4) 0.023* 6.3 (2.0) 0.296 4.4 (1.4) 0.489
No n = 27 22.5 (11.5) 68.3 (21.2) 6.9 (1.2) 4.9 (2.2)
Concentration problems
Yes n = 17 23.1 (18.7) 0.984 79.5 (27.0) 0.407 7.8 (1.3) 0.834 4.8 (1.7) 0.583
No n = 33 23.5 (10.3) 76.6 (32.0) 6.5 (1.7) 4.6 (2.0)
Recovery
Yes n = 28 20.1 (6.4) 0.014* 75.4 (31.5) 0.353 6.4 (1.8) 0.358 4.6 (2.2) 0.904
No n = 22 27.1 (11.5) 27.6 (11.5) 6.9 (1.3) 4.7 (1.6)
Out of work because of
post-LNB
Yes n = 5 30.4 (17.1) 0.253 83.6 (33.4) 0.683 7.0 (1.6) 0.660 4.7 (1.9) 0.296
No n = 45 22.6 (8.4) 70.9 (30.0) 6.6 (1.6) 4.2 (2.3)
TMT, trail-making test; CVLT, California Verbal Learning Test; LNB, Lyme neuroborreliosis; NP, neuropsychological.
*Signiﬁcance level P < 0.05.
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who was blinded to group adherence score the tests and
by matching the patients and controls for demographic
variables like age, educational level, and geographical
region, known to correlate to some degree with intelli-
gence [27]. The fact that the patients chose their con-
trols in their own surroundings will also make the
groups more comparable regarding IQ.
Restriction of patient recruitment to one geographical
region can cause selection bias, but this is unlikely in this
study as the clinical scores and measured improvements
did not diﬀer between the included and not included
patients from the treatment trial. We did not correct for
multiple comparisons with the Bonferroni correction
method as we regard this as too conservative in this study
where the variables are not independent of eachother and
can lead tomissing real diﬀerences as suggested by Bland
and Altman [28]. Strengths of our study are the well-
characterized patients and the controlled design.We also
analyzed factors that could potentially inﬂuence NP test
performance as age, educational level, coexisting dis-
eases, fatigue, malaise, and depression, but found no
correlation between NP test performance and these fac-
tors. Some earlier studies have found a correlation be-
tween cognitive slowing and fatigue in patients with post-
LNB [7], others have not [20,29]. Further investigation
on pathogenesis and outcome in European LNB are
warrnated.
Conclusion
Patients treated for LNB 30 months earlier scored
lower on four NP subtasks assessing processing/
response speed, visual and verbal memory, and execu-
tive/attention functions as compared to matched con-
trols. Most LNB-treated patients performed
comparable to the controls on NP testing, whilst a
subgroup of patients had a debilitating long-term
course with cognitive impairments. The NP test per-
formances were not inﬂuenced by malaise, fatigue, or
depression.
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